CureVac BV might have exploited booming investor interest in messenger RNA (mRNA) vaccines with a massive initial public offering in the US to fund its clinical-stage vaccine against SARS-CoV-2, but its offering on 14 August was relatively modest. The company grossed $213m from the sale of 13.3 million shares at $16 each, although it has now raised more than $1bn in 2020 after financings earlier this year.
Tubingen, Germany-based CureVac has been working on mRNA vaccines for two decades but its work now on a COVID-19 vaccine...






